14 recruiting. 14 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Recruiting 14 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Language Disorders: new trials by email Literature Review of Language Disorders trials Research Report on Language Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Superiority Trial of Aphasia-focused Rehabilitation With tDCS Stimulation tDCS - Aphasia, Broca's Aphasia | Phase 2 / Phase 3 | Recruiting | University of South Carolina | 130 | 2026-07-14 | 2026-07-21 |
| Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder Lumateperone (ITI-007), Placebo Tablet or Capsule - Stuttering, Adult | Phase 2 | Recruiting | CSTrials Inc. | 24 | 2026-04-18 | 2026-07-29 |
| Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia Zenicog, Conventional Speech Therapy - Aphasia, Stroke | Phase 2 | Recruiting | Seoul National University Bundang Hospital | 20 | 2025-12-10 | 2026-02-10 |
| Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST) Semantic Feature Analysis (traditional), Semantic Feature Analysis + Metacognitive Strategy Training - Aphasia, Aphasia Following Cerebral Infarction | Phase 2 | Recruiting | Teachers College, Columbia University | 40 | 2025-07-28 | 2026-06-25 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
| Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia Transcranial Magnetic Stimulation (TMS), Speech-Language Therapy (SLT) - Aphasia, Stroke | Phase 2 | Recruiting | University of Pennsylvania | 24 | 2025-02-11 | 2026-03-05 |
| Communication Bridge 3 Study Communication Bridge™, Evidence-Based Impairment Focused - Primary Progressive Aphasia | Phase 2 | Recruiting | University of Chicago | 200 | 2024-08-23 | 2026-06-01 |
| Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia Transcranial Magnetic Stimulation (TMS), Modified Constraint Induced Language Therapy (mCILT) - Stroke, Aphasia | Phase 2 | Recruiting | University of Pennsylvania | 63 | 2024-08-01 | 2026-06-18 |
| Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia Active tDCS + Language Therapy, Sham tDCS + Language Therapy - Primary Progressive Aphasia, Logopenic Progressive Aphasia | Phase 2 | Recruiting | Johns Hopkins University | 180 | 2024-02-13 | 2026-05-05 |
| Adaptive Trial Scheduling in Naming Treatment for Aphasia Adaptive Spacing Condition, High-Item Non-Adaptive Spacing Condition, Low-Item Non-Adaptive Spacing Condition - Aphasia, Stroke | Phase 2 | Recruiting | University of Pittsburgh | 32 | 2023-12-06 | 2025-12-11 |
| Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia Accuracy-maximized condition, Effort-maximized condition, Effort-accuracy balanced condition - Aphasia, Stroke | Phase 2 | Recruiting | University of Pittsburgh | 30 | 2023-11-27 | 2026-04-13 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| Escitalopram and Language Intervention for Subacute Aphasia Escitalopram 10mg, Placebo, Computer-delivered naming treatment - Aphasia, Stroke | Phase 2 | Recruiting | Johns Hopkins University | 88 | 2021-07-18 | 2026-09-03 |
| Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism Levoleucovorin Calcium, Placebo - Autism Spectrum Disorder, Language Disorders | Phase 2 | Recruiting | Southwest Autism Research & Resource Center | 80 | 2020-10-08 | 2026-04-27 |
Aphasia (9) · Stroke (8) · Aphasia, Primary Progressive (3) · Aphasia, Broca (2) · Communication (2) · Dementia (2) · Frontotemporal Dementia (2) · Alzheimer Disease (1) · Anomia (1) · Aphasia, Conduction (1) · Auditory Diseases, Central (1) · Autism Spectrum Disorder (1) · Hearing Disorders (1) · Hearing Loss (1) · Hearing Loss, Hidden (1)
Communication Disorders (14) · Nervous System Diseases (14) · Neurobehavioral Manifestations (14) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Brain Diseases (12) · Central Nervous System Diseases (12) · Speech Disorders (12) · Cardiovascular Diseases (8) · Cerebrovascular Disorders (8) · Vascular Diseases (8) · Mental Disorders (4) · Frontotemporal Lobar Degeneration (3)
Transcranial Magnetic Stimulation (2) · Capsules (1) · Clemastine (1) · Escitalopram (1) · Language Therapy (1) · Leucovorin (1) · Placebo Effect (1) · Speech Therapy (1) · Transcranial Direct Current Stimulation (1) · lumateperone (1)
Johns Hopkins University (2) · University of Pennsylvania (2) · University of Pittsburgh (2) · AviadoBio Ltd (1) · CSTrials Inc. (1) · Seoul National University Bundang Hospital (1) · Southwest Autism Research & Resource Center (1) · Teachers College, Columbia University (1) · University of Chicago (1) · University of Colorado, Denver (1) · University of South Carolina (1)
United States (13) · Canada (2) · Belgium (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · Sweden (1) · United Kingdom (1)
H. Branch Coslett, MD (2) · William Evans, PhD (2) · Achim Klug, PhD (1) · Argye Hillis-Trupe, MD (1) · Emily Roglaski, PhD (1) · Gerald A Maguire, MD (1) · Kyrana Tsapkini, PhD. (1) · Richard E Frye, MD, PhD (1) · Samuel A Budoff, PhD, MS (1)
PMID 28738099, PMID 31369655, PMID 33642973, PMID 34941929, PMID 42161555
R01DC019325 (2), 2023 (1), P50DC014664 (1), R01AG055425 (1), R01AG075111 (1), R21DC021833 (1), U01DC022447 (1)